| advertise add site services publishers database health videos | ![]() | about toolbar stats live show health store more stuff JOIN/LOGIN |
Update on Plasma and Cryoprecipitate Transfusion itxm.org |
Cryoprecipitate, also called "Cryoprecipitated Antihemophilic Factor", "Cryoprecipitated AHF", and most commonly just "cryo", is a frozen blood product prepared from plasma. It is often transfused as a four to six unit pool instead of as a single product. Many uses of the product have been replaced by factor concentrates, but it is still routinely stocked by many hospital blood banks. Like fresh frozen plasma, compatibility testing is not indicated, but it is given as ABO compatible. Compatibility is reversed for plasma products: AB type is the universal plasma donor and O type is the universal plasma recipient.
[edit] CompositionEach 15 mL unit typically contains 100 IU of factor VIII, and 250 mg of fibrinogen. It also contains von Willebrand factor (vWF) and factor XIII. US standards require manufacturers to test at least four units each month, and the products must have an average of 150 mg or more of fibrinogen and 80 IU of factor VIII.[1] Individual products may actually have less than these amounts as long as the average remains above these minimums. Typical values for a unit are substantially higher, and aside from infants it is rare to transfuse just one unit. [edit] IndicationsIndications for giving cryoprecipitate include:[2]
[edit] ManufactureThe product is manufactured by slowly thawing a unit of FFP at temperatures just above freezing (1-6 °C), typically in a water bath or a refrigerator. The product is then centrifuged to remove the majority of the plasma, and the precipitate is resuspended in the remaining plasma or in sterile saline. The product may be pooled and frozen or frozen as individual units. [edit] HistoryThe first publication of the method of concentrating clotting factors from plasma was by Judith Graham Pool at Stanford University in 1964, writing in Nature.[3] Cryoprecipitate was originally known as "Cryoprecipitate AHF", where AHF stands for "Anti-hemophiliac factor." AHF is now known as Factor VIII. According to Dr. Charles Abildgaard, who was a Stanford medical resident at the time:
Others had been close to discovering cryoprecipitate but failed to make the connection between the lack of plasma clotting activity after thawing and the precipitate. According to Dr. Frederick Rickles:
[edit] References
| |||||||||||||
| ↑ top of page ↑ | about thumbshots |